Immatics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Immatics and other ETFs, options, and stocks.About IMTX
Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its pipeline includes adoptive cell therapy and TCR Bispecifics.
CEOHarpreet Singh-Jasuja
CEOHarpreet Singh-Jasuja
Employees423
Employees423
HeadquartersTuebingen, Baden Wuerttemberg
HeadquartersTuebingen, Baden Wuerttemberg
Founded2020
Founded2020
Employees423
Employees423
IMTX Key Statistics
Market cap1.33B
Market cap1.33B
Price-Earnings ratio-9.28
Price-Earnings ratio-9.28
Dividend yield—
Dividend yield—
Average volume353.99K
Average volume353.99K
High today$10.10
High today$10.10
Low today$9.76
Low today$9.76
Open price$10.10
Open price$10.10
Volume275.51K
Volume275.51K
52 Week high$12.41
52 Week high$12.41
52 Week low$3.30
52 Week low$3.30
Stock Snapshot
Immatics(IMTX) stock is priced at $9.91, giving the company a market capitalization of 1.33B. It carries a P/E multiple of -9.28.
During the trading session on 2026-01-23, Immatics(IMTX) shares reached a daily high of $10.10 and a low of $9.76. At a current price of $9.91, the stock is +1.5% higher than the low and still -1.9% under the high.
Trading activity shows a volume of 275.51K, compared to an average daily volume of 353.99K.
Over the past 52 weeks, Immatics(IMTX) stock has traded between a high of $12.41 and a low of $3.30.
Over the past 52 weeks, Immatics(IMTX) stock has traded between a high of $12.41 and a low of $3.30.
Analyst ratings
100%
of 11 ratingsBuy
100%
Hold
0%
Sell
0%
People also own
Based on the portfolios of people who own IMTX. This list is generated using Robinhood data, and it’s not a recommendation.